MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Kodu・Aktsiate loetelu・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Suletud

SektorTervishoid

212.91

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

211.78

Max

212.99

Põhinäitajad
By Trading Economics
Sissetulek	-22M -61M
Müük	56M 214M
Kasumimarginaal	-28.549
Töötajad	1,017
EBITDA	-56M -53M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+23.5% upside

Turustatistika
By TradingEconomics
Turukapital	1B 13B
Eelmine avamishind	212.91
Eelmine sulgemishind	212.91

Uudiste sentiment

By Acuity

50%

142 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

157.66 / 167.29 Toetus ja vastupanu

Ascendis Pharma A-S ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. jaan 2026, 22:45 UTC

Suurimad hinnamuutused turgudel

GH Research Shares Up, Plans to Provide Update on New Drug Application

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

4. jaan 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

4. jaan 2026, 23:40 UTC

Market Talk

Uudisväärsed sündmused

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

4. jaan 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 23:17 UTC

Uudisväärsed sündmused

Spot Gold Rises 0.8% to $4,365.24/oz

4. jaan 2026, 23:16 UTC

Uudisväärsed sündmused

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

4. jaan 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

4. jaan 2026, 23:13 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

4. jaan 2026, 23:12 UTC

Market Talk

Uudisväärsed sündmused

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 22:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

4. jaan 2026, 21:00 UTC

Tulu

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

3. jaan 2026, 18:59 UTC

Uudisväärsed sündmused

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 17:42 UTC

Uudisväärsed sündmused

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

3. jaan 2026, 17:40 UTC

Uudisväärsed sündmused

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 16:10 UTC

Uudisväärsed sündmused

What Maduro's Capture Means for Chevron Stock -- Barrons.com

3. jaan 2026, 15:53 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 15:03 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 14:10 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 12:16 UTC

Uudisväärsed sündmused

U.S. Captures Maduro, Trump Says -- Barrons.com

3. jaan 2026, 09:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

3. jaan 2026, 09:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

3. jaan 2026, 00:43 UTC

Omandamised, ülevõtmised, äriostud

Research Reports -- Barrons.com

2. jaan 2026, 22:13 UTC

Market Talk

Tulu

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Ascendis Pharma A-S ADR Prognoos

Hinnasiht

By TipRanks

23.5% tõus

12 kuu keskmine prognoos

Keskmine 263.42 USD 23.5%

Kõrge 325 USD

Madal 220 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Ascendis Pharma A-S ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi Ascendis Pharma A-S ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

157.66 / 167.29Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

142 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.